Onxeo collaborates with the Royal College of Surgeons in Ireland for research program on Beleodaq® derivatives

PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE (http://www.businesswire.com/))--
Regulatory News:

Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ Copenhagen:
ONXEO), an innovative company specializing in the development of orphan oncology
therapeutics, today announced a collaboration with the Royal College of Surgeons
in Ireland (RCSI) for a discovery-stage program on the derivatives of belinostat
(Beleodaq®), a histone deacetylase (HDAC) inhibitor.

This new collaboration program aims at optimizing the pharmacokinetic profile of
belinostat, in order to increase its lifetime, its efficacy and its stability.
In the end, the goal is to develop conjugate molecules derived from belinostat
and with distinctive features compared to existing HDAC inhibitors, which may
lead to new patent opportunities. The research projects will be led by Pr.
Celine Marmion, Associate Professor of Bioinorganic Chemistry at RCSI and
specialized in rational drug design, synthesis and pharmacological evaluation of
metal-based anti-cancer agents.

According to the terms of the agreement, research costs will be shared between
Onxeo and RCSI. Onxeo will have an option to license RCSI’s patents at
negotiated rates. RCSI will lead compounds synthesis and in vitro testing, and
Onxeo will lead the in vivo studies.

“We are excited to partner with leading research institution such as RCSI for
this preclinical program which should allow us to develop new compounds derived
from belinostat. This will enable us to strengthen our portfolio while
capitalizing on the experience already acquired with this product. Results of
these researches are expected in the course of 2017,” commented Judith Greciet,
CEO of Onxeo.

The concept for such a derived conjugated belinostat was validated by similar
work described in a safety and efficacy presentation at the American Society of
Hematology (ASH) Annual Meeting in 2011.

About Onxeo

Onxeo is a leading developer of orphan oncology drugs. The Company is focused on
developing innovative therapeutics for rare cancers, one of the fastest growing
markets in the healthcare industry with high, unmet medical needs. Onxeo’s
vision is to become a global leader and pioneer in oncology, with a focus on
orphan or rare cancers, by developing advanced, effective, and safe therapeutics
designed to improve the lives of patients. Onxeo’s comprehensive portfolio
features a broad orphan oncology pipeline, with four independent programs in
various stages of clinical development, including Onxeo’s first approved orphan
oncology drug, Beleodaq®. The Company is headquartered in Paris, France and has
approximately 50 employees. Onxeo is listed on Euronext in Paris, France
(Ticker: ONXEO, ISIN Code: FR0010095596) and Nasdaq Copenhagen, Denmark (Ticker:
ONXEO).

Onxeo’s orphan oncology products are:

  · Livatag® (Doxorubicin Transdrug™): Currently being evaluated in a Phase III
trial (ReLive) in patients with hepatocellular carcinoma (primary liver cancer);
and in combination with other cancer agents in first-line HCC
  · Beleodaq® (belinostat): FDA-approved in the US in 2014 under the agency’s
accelerated approval program as a second-line treatment for patients with
peripheral T-cell lymphoma (PTCL) and currently marketed by Onxeo’s partner in
the US, Spectrum Pharmaceuticals; belinostat in combination with other cancer
agents is currently in development in first-line treatment for patients with
PTCL (BelCHOP) and in other solid tumors
  · AsiDNA: The first-in-class siDNA (signal-interfering DNA) which has
successfully undergone a proof-of-concept Phase I trial in metastatic melanoma
  · Validive® (Clonidine Lauriad®): Positive final results from a Phase II trial
in head and neck cancer patients with severe oral mucositis
In addition, Onxeo has successfully developed and registered two non-cancer
products which are currently being commercialized in the U.S. and Europe.

Learn more by
visiting www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%
3 
A%2F%2Fwww.onxeo.com&esheet=51376945&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=1&md5=ff351345f91eb9d304c41d8e5a6079f6).

To receive our press releases and newsletters, please register
on: http://www.onxeo.com/en/newsletter/ (http://cts.businesswire.com/ct/CT?id=sm
a 
rtlink&url=http%3A%2F%2Fwww.onxeo.com%2Fen%2Fnewsletter%2F&esheet=51376945&newsi
t 
emid=0&lan=en
-US&anchor=http%3A%2F%2Fwww.onxeo.com%2Fen%2Fnewsletter%2F&index=2&md5=15fde420f
2 
d55c137e98d2f869599a3b)
Follow us on Twitter: @Onxeo_

Disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Onxeo and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors, which could cause the
actual results, financial condition, performance or achievements of Onxeo to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Onxeo is providing this
communication as of this date and does not undertake to update any forward
-looking statements contained herein as a result of new information, future
events or otherwise. For a discussion of risks and uncertainties which could
cause actual results, financial condition, performance or achievements of Onxeo
to differ from those contained in the forward-looking statements, please refer
to the Risk Factors ("Facteurs de Risque") section of the 2015 Reference
Document filed with the AMF on April 29, 2016, which is available on the AMF
website (http://www.amf
-france.org (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww
. 
amf-france.org&esheet=51376945&newsitemid=0&lan=en
-US&anchor=http%3A%2F%2Fwww.amf
-france.org&index=3&md5=a82d71ca561af3b34896850346208f1e)) or on the company’s
website
(www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2F
w 
ww.onxeo.com&esheet=51376945&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=4&md5=26a62aa597a71404a22dd0aed6b3442e)).
Onxeo S.A.
Judith Greciet, CEO
Nicolas Fellmann, CFO
+33 1 45 58 76 00
contact@onxeo.com
or
Alize RP (France)
Caroline Carmagnol / Florence Portejoie, +33 6 64 18 99 59 / +33 6 47 38 90 04
onxeo@alizerp.com
or
The Ruth Group (U.S.)
Kirsten Thomas / Lee Roth, +1-508-280-6592 / +1-646-536-7012
kthomas@theruthgroup.com / lroth@theruthgroup.com